title: Systems Pharmacology Dissection of the Protective Effect of Myricetin Against Acute Ischemia/Reperfusion-Induced Myocardial Injury in Isolated Rat Heart.
abstract: In this paper, we investigated the multi-target effect of myricetin as a therapeutic for cardiovascular disease, using an acute ischemia/reperfusion-induced myocardial injury model to gain insight into its mechanism of action. The compound-target interaction profiles of myricetin were determined using a combination of text mining, chemometric and chemogenomic methods. The effect of myricetin on cardiac function was investigated by carrying out experiments in rats subjected to ischemia/reperfusion (I/R) using Langendorff retrograde perfusion technology. Compared to the I/R group, pretreatment with 5 μM myricetin was observed to improve the maximum up/down rate of left ventricular pressure (dp/dtmax) and coronary flow, raise left ventricular developed pressure, and decrease creatine kinase and lactate dehydrogenase levels in coronary flow. In addition, myricetin treatment was shown to have beneficial effects through its ability to reduce both infarct size and levels of cardiomyocyte apoptosis. Myricetin was also observed to have antioxidant properties, as evidenced by its ability to reduce MDA levels, while increasing both SOD levels and the GSH/GSSG ratio. Finally, an upregulation of 6-phosphogluconate dehydrogenase and fatty acid synthase expression and a downregulation of cyclooxygenase-2, cytochrome P450 and p38 mitogen-activated protein kinase expression suggest that myricetin acts through mechanisms which alter relevant signaling pathways. In summary, our results demonstrate that myricetin has protective cardiovascular effects against I/R-induced myocardial injury.
authors.affiliation: Weihai Central Hospital, Wendeng, 264400, Shandong, China.
authors.forename: Yingna
authors.initials: Y
authors.lastname: Qiu
authors.affiliation: Rushan Hospital Of Traditional Chinese Medicine, Weihai, 264200, Shandong, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Cong
authors.affiliation: Weihai Central Hospital, Wendeng, 264400, Shandong, China.
authors.forename: Meng
authors.initials: M
authors.lastname: Liang
authors.affiliation: Weihai Central Hospital, Wendeng, 264400, Shandong, China.
authors.forename: Yongqiang
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Weihai Central Hospital, Wendeng, 264400, Shandong, China. wjs8474046@163.com.
authors.forename: Jianshe
authors.identifier: 0000-0001-9463-0529
authors.initials: J
authors.lastname: Wang
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005419:Flavonoids / Q000494:pharmacology / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D000067268:Isolated Heart Preparation / Q000379:methods; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D002316:Cardiotonic Agents; D005419:Flavonoids; C040015:myricetin
keywords: Anti-inflammatory; Antioxidant; Cardioprotection; Ischemia/reperfusion; Multi-target; Myricetin